SecBot SecBot
6-K ·Filed Jun 4, 2026

PHAR

Pharming Group N.V.
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago SEC0001828316-26-000031
Notable filing: 6-K
Actionable Insight ▲ Bullish

The next key catalyst is the PDUFA date on October 24, 2026. Monitor for any FDA advisory committee briefing documents or pre-meeting communications between now and then. The separate sNDA for lower-weight patients (planned H2 2026) adds a second catalyst. The prior CRL and resubmission process introduces some residual regulatory risk, but acceptance indicates the FDA views the package as substantially complete.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.47
T+0 close · Jun 4, 2026 · via day close
Latest settled
−6.17%
T+60 · $11.70
Vs SPY
−8.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 4 $12.47entry
  2. T+1 · 6mo ago +0.57%α +3.17% · $12.54
  3. T+5 · 5mo ago +3.29%α +5.84% · $12.88
  4. T+20 · 4mo ago +10.43%α +11.80% · $13.77
  5. T+60 · 3mo ago −6.17%α −8.06% · $11.70

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharming announced FDA acceptance of its resubmitted sNDA for Joenja (leniolisib) to treat children aged 4-11 with APDS, with a PDUFA date of October 24, 2026. The resubmission follows a prior Complete Response Letter (CRL) in January 2026 and addresses FDA requests on analytical methods. If approved, Joenja would be the first U.S. treatment for pediatric APDS, expanding the addressable patient population and bolstering the product's lifecycle.

Key Facts

  • FDA accepted resubmitted sNDA for Joenja in children aged 4-11 with APDS
  • PDUFA target action date: October 24, 2026
  • Resubmission follows Complete Response Letter (Jan 30, 2026) and Type A meeting (Mar 26, 2026)
  • Seeks approval for 40 mg and 50 mg twice-daily dosing for patients weighing ≥27 kg
  • Separate sNDA for lower-weight pediatric patients (<27 kg) planned for second half 2026
  • Phase III data showed improvements in lymphadenopathy and naïve B cells over 12 weeks with no drug-related serious adverse events
  • Joenja already approved for patients 12+ in the U.S. (March 2023), U.K., Australia, Israel, and Japan (4+)

Financial Impact

If approved, Joenja's pediatric label expansion could meaningfully broaden the treatable APDS population (1-2 per million), adding incremental revenue beyond the current adult/adolescent indication. No financial terms or revenue figures were disclosed in the filing.

revenue

Risk Factors

  • FDA could issue a second CRL on or before the PDUFA date despite acceptance of the resubmission
  • The separate sNDA for lower-weight patients has not yet been filed and may face its own regulatory hurdles
  • Joenja faces potential competition from other PI3K inhibitors in development for APDS
  • Commercial uptake in the pediatric population depends on diagnosis rates and payer coverage

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001828316-26-000031
Document: 0001828316-26-000031-index-headers.html0001828316-26-000031
Document: 0001828316-26-000031-index.html0001828316-26-000031
Document: 0001828316-26-000031.txt0001828316-26-000031

Track record

18 reports on PHAR

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 10 of 14 went positive at some point.

Filters
  1. Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
  2. Nov 6, 202611d ago Press Release Bullish 6/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
  3. Oct 27, 202620d ago 6-K Bullish 6/10 No price data
  4. Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
  5. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
  6. Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
  7. Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
  8. Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
  9. Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
  10. Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026